6-氯-3-联苯胺 | 56970-25-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-氯-3-联苯胺
• 英文名称: 6-chloro-[1,1'-biphenyl]-3-amine
• 英文别名: 6-chloro-biphenyl-3-ylamine；6-Chlor-biphenyl-3-ylamin；4-chloro-3-phenylaniline
• CAS: 56970-25-3
• 化学式: C₁₂H₁₀ClN
• 分子量: 203.671
• InChiKey: BSDFOSUPRZEWQI-UHFFFAOYSA-N

物化性质

• 沸点：
  354.2±30.0 °C(Predicted)
• 密度：
  1.205±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-氯-3-联苯胺 在 肼 作用下， 以 甲醇 、 异丙醇 为溶剂， 反应 1.0h， 生成
  参考文献：
  名称：

  A comparative study of fragment screening methods on the p38α kinase: new methods, new insights

  摘要：

  利用 BioFocus 片段库评估了一种基于片段的药物发现方法，即应激活化激酶 p38α。在 Biacore™ T100 上通过表面等离子体共振 (SPR) 针对 p38α 和两个选择性目标筛选化合物。我们对文库中的一个子集进行了详细的后续分析，包括对 24 个已确认的选择性命中物进行命中确认、亲和力测定，以及这些命中物与已知 ATP 结合位点抑制剂的竞争分析。此外，还使用迁移率平台（LC3000，Caliper LifeSciences）在生化试验中评估了针对 p38α 的功能活性。还利用荧光寿命（FLEXYTE™）和微尺度热电泳（Nanotemper）技术对部分片段进行了评估。不同检测方法的数据之间具有良好的相关性。解决了四种小分子与 p38α 复合物的晶体结构问题。有趣的是，通过 X 射线分析和 SPR 竞争实验确定，其中三个复合物涉及 ATP 结合位点上的片段，而第四个化合物则结合在一个远端位点上，该位点有可能成为新型药物的靶点。围绕远程结合位点片段进行的第一轮优化，确定了一系列含三唑的化合物。这种方法可作为开发新型活性 p38α 抑制剂的基础。更广泛地说，它说明了结合一系列生物物理和生物化学技术发现片段的威力，这些片段有助于开发激酶和其他药物靶点的新型调节剂。

  DOI：

  10.1007/s10822-011-9454-9
• 作为产物：
  描述：

  1-氯-2-碘-4-硝基苯 在 四(三苯基膦)钯 、 铁粉 、 sodium carbonate 、 氯化铵 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 27.0h， 生成 6-氯-3-联苯胺
  参考文献：
  名称：

  Discovery of 1-(3-aryl-4-chlorophenyl)-3-( p -aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings

  摘要：

  PI3K/Akt/mTOR and hedgehog (Hh) signalings are two important pathways in breast cancer, which are usually connected with the drug resistance and cancer migration. Many studies indicated that PI3K/Akt/ mTOR inhibitors and Hh inhibitors displayed synergistic effects, and the combination of the two signaling drugs could delay drug resistance and inhibit cancer migration in breast cancer. Therefore, the development of molecules simultaneously inhibiting these two pathways is urgent needed. Based on the structures of P13K inhibitor buparlisib and Hh inhibitor vismodegib, a series of hybrid structures were designed and synthesized utilizing rational drug design and computer-based drug design. Several compounds displayed excellent antiproliferative activities against several breast cancer cell lines, including triple-negative breast cancer (TNBC) MDA-MB-231 cell. Further mechanistic studies demonstrated that the representative compound 9i could inhibit both PI3K/Akt/mTOR and hedgehog (Hh) signalings by inhibiting the phosphorylation of S6K and Akt as well as decreasing the SAG elevated expression of Gli1. Compound 9i could also induce apoptosis remarkably in T47D and MDA-MB-231 cells. In the transwell assay, 9i showed significant inhibition on the migration of MDA-MB-231. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.09.002

文献信息

• [EN] NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS<br/>[FR] NOUVEAUX AGENTS ANTIDIABÉTIQUES UTILES AVEC DES DÉRIVÉS DE BENZIMIDAZOLE CYCLIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2010051176A1

  公开（公告）日：2010-05-06

  Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

  结构式（I）的新化合物是AMP-蛋白激酶的激活剂，可用于治疗、预防和抑制由AMPK激活的蛋白激酶介导的疾病。本发明的化合物对于治疗2型糖尿病、高血糖、代谢综合征、肥胖、高胆固醇血症和高血压是有用的。
• Catalyst-Controlled Regioselective Chlorination of Phenols and Anilines through a Lewis Basic Selenoether Catalyst
  作者：Andrew N. Dinh、Sean M. Maddox、Sagar D. Vaidya、Mirza A. Saputra、Christopher J. Nalbandian、Jeffrey L. Gustafson

  DOI：10.1021/acs.joc.0c01917

  日期：2020.11.6

  ortho-selective electrophilic chlorination of phenols utilizing a Lewis basic selenoether catalyst. The selenoether catalyst resulted in comparable selectivities to our previously reported bis-thiourea ortho-selective catalyst, with a catalyst loading as low as 1%. The new catalytic system also allowed us to extend this chemistry to obtain excellent ortho-selectivities for unprotected anilines. The selectivities

  我们报道了利用路易斯碱性硒醚催化剂对苯酚的高效邻位选择性亲电子氯化。硒醚催化剂的选择性与我们先前报道的双硫脲邻位选择性催化剂相当，催化剂负载量低至1％。新的催化系统还使我们能够扩展这种化学反应，从而获得对未保护的苯胺的优异的邻位选择性。该反应的选择性高达> 20：1邻/对，而对苯酚和苯胺的固有选择性约为1：4邻/对。一系列初步研究表明，底物需要一个氢键部分才能实现选择性。
• NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES
  申请人：Bayer CropScience Aktiengesellschaft

  公开号：US20200062729A1

  公开（公告）日：2020-02-27

  The invention relates to novel compounds of the formula (I) in which Z, Y, A 1 , A 2 , A 3 , A 4 , X, R 7 , R 8 and R 9 have the meanings mentioned above, and processes and intermediates for the preparation thereof, and their use for controlling animal pests, in particular insects.

  该发明涉及公式（I）中的新化合物，其中Z、Y、A1、A2、A3、A4、X、R7、R8和R9具有上述提及的含义，以及其制备的过程和中间体，以及它们用于控制动物害虫，特别是昆虫。
• Structurally Simple Inhibitors of Lanosterol 14α-Demethylase Are Efficacious In a Rodent Model of Acute Chagas Disease
  作者：Praveen Kumar Suryadevara、Srinivas Olepu、Jeffrey W. Lockman、Junko Ohkanda、Mandana Karimi、Christophe L. M. J. Verlinde、James M. Kraus、Jan Schoepe、Wesley C. Van Voorhis、Andrew D. Hamilton、Frederick S. Buckner、Michael H. Gelb

  DOI：10.1021/jm900030h

  日期：2009.6.25

  We report structure-activity studies of a large number of dialkyl imidazoles as inhibitors of Trypanosoma cruzi lanosterol-14 alpha-demethylase (L14DM). The compounds have a simple structure compared to posaconazole, another L14DM inhibitor that is an anti-Chagas drug candidate. Several compounds display potency for killing T cruzi amastigotes in vitro with values of EC50 in the 0.4-10 nM range. Two compounds were selected for efficacy studies in a mouse model of acute Chagas disease. At oral doses of 20-50 mg/kg given after establishment of parasite infection, the compounds reduced parasitemia in the blood to undetectable levels, and analysis of remaining parasites by PCR revealed a lack of parasites in the majority of animals. These dialkyl imidazoles are substantially less expensive to produce than posaconazole and are appropriate for further development toward an anti-Chagas disease clinical candidate.
• Discovery of novel N,N-3-phenyl-3-benzylaminopropionanilides as potent inhibitors of cholesteryl ester transfer protein in vivo
  作者：Honglei Xie、Yiqun Li、Changlin Bai、Ruifeng Wang、Chunchi Liu、Chenzhou Hao、Bin Lin、Maosheng Cheng、Dongmei Zhao

  DOI：10.1016/j.bmc.2016.03.002

  日期：2016.4

  Epidemiological studies have identified that the risk of cardiovascular events increases due to the decreased levels of high density lipoprotein-cholesterol and the elevated levels of low density lipoprotein-cholesterol. Herein, we report a novel series of N,N-3-phenyl-3-benzylaminopropionanilide derivatives, which were identified as potent cholesteryl ester transfer protein (CETP) inhibitor. The initial lead compound L10 (IC50 8.06 mu M) was found by pharmacophore-based virtual screening (Dong-Mei Zhao et al., Chin. Chem. Lett. 2014, 25, 299). After systematic structure variation and biological testing against CETP, two different series were identified as scaffolds for potent CETP inhibitors. One is N,N-3-phenyl-3-benzylaminopropanamide derivatives, which were investigated in our previous paper (Bioorg. Med. Chem. 2015, doi: http://dx.doi.org/10.1016/j.bmc.2015.12.010). The most potent compound HL16 in that series has the IC50 of 0.69 mu M. The other series is N, N-3-phenyl-3-benzylaminopropionanilide derivatives, which was investigated in current study. Further optimization of the structure-activity relationship (SAR) resulted in H16 (IC50 0.15 mu M), which was discovered as a potent CETP inhibitor in vitro by BODIPY-CE fluorescence assay. In addition, the results of pharmacodynamics studies showed that H16 exhibited both favorable HDL-C enhancement and LDL-C reduction in vivo by hamster. It also has an excellent stability in rat liver microsomal. (C) 2016 Elsevier Ltd. All rights reserved.